Skip to main content
. 2022 May 24;29(6):3825–3848. doi: 10.3390/curroncol29060306

Table 3.

Studies in which SIRT and chemotherapy were given concomitantly to at least 1 patient.

Author, Year, Type of Study No. of Patients Receiving Concomitant Chemotherapy/Total Number of Patients Chemotherapy Regimen Definition Analysis
Depalo, T. et al. (2021) RS [25] 7/15 - No definitions available. Concomitant chemotherapy was distinct from chemotherapy given before SIRT. No significant difference in SIRT + chemo vs. SIRT alone, in terms of radiosensitivity (p value not available).
Paz-Fumagalli, R. et al. (2021) RS [26] - Cisplatin + gemcitabine Concomitant chemotherapy was administered in 45 days before or after SIRT. Unified results
Riby, D. et al.
(2020) RS [29]		 18/19

  1. Cisplatin 50 mg/m2 + 5FU 400 mg/m2

  2. Cisplatin 80 mg/m2 + capecitabine 1000 mg/m2

  3. Gemcitabine 1000 mg/m2 + oxaliplatin 100 mg/m2

  4. Cisplatin 25 mg/m2 + gemcitabine 1000 mg/m2

  5. Oxaliplatin 85 mg/m2 + irinotecan 180 mg/m2 + 5FU 400 mg/m2

(Gemcitabine reduced to 300 mg/m2 for concomitant administration)		 Concomitant chemotherapy was administered on the day before or the day after SIRT, but not on the same day. SIRT + chemo vs. chemo vs. surgery: RFS and recurrence rate statistically the same (p = 0.28 and p = 0.21, respectively).
Edeline, J. et al. (2020) PS [33] 41/41 Cisplatin 25 mg/m2 + gemcitabine 1000 mg/m2
(Gemcitabine reduced to 300 mg/m2 for concomitant
administration)		 SIRT administered in cycle 1 for ICC (one hemi-liver)
or in
cycles 1 and 3 (both hemi-livers)		 9 patients (22%) successfully down-staged to surgical resection.
Buettner, S. et al. (2020) RS [34] 4/114

  1. 5FU-based

  2. Cisplatin + gemcitabine

 No definitions available. Concomitant chemotherapy was distinct from chemotherapy given before or after SIRT. -
White, J. et al.
(2019) RS [37]		 7/61 - No definitions available. Concomitant chemotherapy was distinct from chemotherapy given before or after SIRT. -
Bourien, H. et al. (2019) RS [39] 33/64

  1. Cisplatin 50 mg/m2 + 5FU 400 mg/m2 (bolus)

  2. Gemcitabine 1000 mg/m2 + oxaliplatin 100 mg/m2

  3. Cisplatin 25 mg/m2 + gemcitabine 1000 mg/m2

  4. Gemcitabine 1250 mg/m2

(Gemcitabine reduced to 300 mg/m2 for concomitant administration)		 Chemotherapy was administered at most 3 months before SIRT. Chemotherapy administered more than 3 months before SIRT was considered induction chemotherapy. Median PFS and median OS were not statistically different for the concomitant chemotherapy vs. induction vs. no chemotherapy groups
(p = 0.90; p = 0.37, respectively).
Manceau, V. et al. (2018) RS [44] 35/35

  1. Cisplatin 25 mg/m2 + gemcitabine 1000 mg/m2

  2. Cisplatin 50 mg/m2 + 5FU 400 mg/m2

  3. Gemcitabine 1000 mg/m2 + oxaliplatin 100 mg/m2

(Gemcitabine reduced to 300 mg/m2 for concomitant administration)		 Chemotherapy administered at most 3 months before SIRT. The exact tumor dose threshold for response in SIRT concomitant with chemotherapy could not be defined, but was below 158 Gy.
17 patients (49%) had successful downstaging.
Akinwande, O. et al.
(2017) RS [48]		 4/25 - - The disease control rate was not affected by concomitant chemotherapy administration (p = 0.99)
Pieper, C. C. et al. (2016) RS [50] 1/26 - - Unified analysis of SIRT application for different malignancies revealed concurrent chemotherapy is a predictor of stasis in SIRT (OR, 8.69; p = 0.00)
Edeline, J. et al. (2015) RS [54] 10/24

  1. Cisplatin 50 mg/m2 + 5FU 400 mg/m2

  2. Gemcitabine 1000 mg/m2 + oxaliplatin 100 mg/m2

  3. Cisplatin 25 mg/m2 + gemcitabine 1000 mg/m2

(Gemcitabine reduced to 300 mg/m2 for concomitant administration)		 Chemotherapy administered at most 3 months before SIRT. The median PFS was higher in the concomitant chemotherapy group than in the induction group (p = 0.00).
Nezami, N. et al. (2019) PS [69] 5/5 Gemcitabine
Dose level 1: 400 mg/m2
Dose level 2: 600 mg/m2
Dose level 3: 800 mg/m2
Dose level 4: 1000 mg/m2 		Chemotherapy on one day before SIRT for 1-lobe treatment and 38 days before SIRT for 2-lobe treatment. No gemcitabine-related toxicity on dose levels 1 and 2. All hepatic toxicities were on dose level 4. RECIST at 3 m: 100% stable disease.

NA: not available, OS: overall survival; PFS, progression-free survival; PS, prospective study; pts, patients; RECIST, Response Evaluation Criteria in Solid Tumors; RFS, recurrence-free survival; RS, retrospective study; SIRT, selective internal radiation therapy.